secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001628280-26-024831
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission
--------------------------------------------------------------------------------

- SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.
- Secondary endpoints: clinical remission 40%, endoscopic improvement 51%, Modified Mayo Score change -3.7.
- Well tolerated: 6 TEAEs (14%), 1 SAE deemed not drug-related; no drug-related AEs or discontinuations.
- Part A enrollment closed; Part B enrolling monotherapy (SPY001/002/003) and combination cohorts.
- Proof-of-concept data expected mid-2026 for SPY002, Q3 2026 for SPY003; Part B data on track for 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/0001628280-26-024831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/syre-20260413.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-024831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer